載入中
Lantern Pharma Inc. is a clinical-stage biotechnology firm dedicated to revolutionizing drug development through the strategic application of artificial intelligence, machine learning, and comprehensive genomic data analysis. Their primary drug candidate, LP-100, is currently undergoing Phase II clinical trials, targeting metastatic, castration-resistant prostate cancer. The company is also advancing LP-300 as a potential combination therapy for non-small cell lung cancer adenocarcinoma, specifically in individuals who are non-smokers or have never smoked. Furthermore, their preclinical pipeline includes LP-184, an alkylating agent engineered to inflict DNA damage upon cancer cells that either overexpress specific biomarkers or exhibit mutations within their DNA repair pathways. Beyond these, Lantern Pharma maintains an antibody-drug conjugate (ADC) program for diverse cancer treatments. Central to their operations is the RADR artificial intelligence platform, which synergizes molecular data through advanced big data analytics and machine learning capabilities. Established in 2013, the company operates from its headquarters in Dallas, Texas.
前收盤價
US$0.737
−US$0.0757 · -9.31%
盤前
US$0.7238
−US$0.0132 · -1.79%
10月13日 上午4:00 ET
盤中時間採用ET。市場資料可能有所延遲。
Lantern Pharma Inc. is a clinical-stage biotechnology firm dedicated to revolutionizing drug development through the strategic application of artificial intelligence, machine learning, and comprehensive genomic data analysis. Their primary drug candidate, LP-100, is currently undergoing Phase II clinical trials, targeting metastatic, castration-resistant prostate cancer. The company is also advancing LP-300 as a potential combination therapy for non-small cell lung cancer adenocarcinoma, specifically in individuals who are non-smokers or have never smoked. Furthermore, their preclinical pipeline includes LP-184, an alkylating agent engineered to inflict DNA damage upon cancer cells that either overexpress specific biomarkers or exhibit mutations within their DNA repair pathways. Beyond these, Lantern Pharma maintains an antibody-drug conjugate (ADC) program for diverse cancer treatments. Central to their operations is the RADR artificial intelligence platform, which synergizes molecular data through advanced big data analytics and machine learning capabilities. Established in 2013, the company operates from its headquarters in Dallas, Texas.
日內區間
目前US$0.737
52週區間
目前US$0.737
盤中時間採用ET。市場資料可能有所延遲。
Lantern Pharma Inc. is a clinical-stage biotechnology firm dedicated to revolutionizing drug development through the strategic application of artificial intelligence, machine learning, and comprehensive genomic data analysis. Their primary drug candidate, LP-100, is currently undergoing Phase II clinical trials, targeting metastatic, castration-resistant prostate cancer. The company is also advancing LP-300 as a potential combination therapy for non-small cell lung cancer adenocarcinoma, specifically in individuals who are non-smokers or have never smoked. Furthermore, their preclinical pipeline includes LP-184, an alkylating agent engineered to inflict DNA damage upon cancer cells that either overexpress specific biomarkers or exhibit mutations within their DNA repair pathways. Beyond these, Lantern Pharma maintains an antibody-drug conjugate (ADC) program for diverse cancer treatments. Central to their operations is the RADR artificial intelligence platform, which synergizes molecular data through advanced big data analytics and machine learning capabilities. Established in 2013, the company operates from its headquarters in Dallas, Texas.
日內區間
目前US$0.737
52週區間
目前US$0.737
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 銷貨成本 | — | — | 17.48萬 USD | — | — |
| 毛利 | — | — | −17.48萬 USD | — | — |
| 研究與開發 | 1151.41萬 USD | 1612.57萬 USD | 1189.43萬 USD | 86.03億 USD | 757.06萬 USD |
| 銷售、一般及管理費用 | 646.44萬 USD | 609.07萬 USD | 598.33萬 USD | 58.3億 USD | 502.09萬 USD |
| 營業費用 | 1797.85萬 USD | 2221.64萬 USD | 1770.27萬 USD | 144.33億 USD | 1259.15萬 USD |
| 利息收入 | 43.79萬 USD | 74.24萬 USD | 76.54萬 USD | 2.04億 USD | 6.79萬 USD |
| 折舊和攤銷 | 1.73萬 USD | 1.73萬 USD | 1.46萬 USD | 1.01萬 USD | 6761 USD |
| 營業利益 | −1797.85萬 USD | −2221.64萬 USD | −1787.76萬 USD | −144.33億 USD | −1259.15萬 USD |
| 淨利 | −1711.94萬 USD | −2078.12萬 USD | −1596.15萬 USD | −142.6億 USD | −1236.3萬 USD |
公司資料更新於 2026年10月13日。
近期已公布業績
近期已公布業績
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI68.69萬0.00%2.3兆 USD0.03%US$381.57-0.10%
Vanguard Extended Market ETFVXF16.63萬0.00%954億 USD0.05%US$233.52-0.63%
Horizon Kinetics Medical ETFMEDX1.68萬0.10%1656.51萬 USD0.85%US$35.2544+1.60%
Dimensional - US Sustainability Core 1 ETFDFSU1417.990.00%23.92億 USD0.15%US$48.13+0.04%
Dimensional - US Core Equity 2 ETFDFAC522.570.00%885.96億 USD0.21%US$45.31-0.04%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFHorizon Kinetics Medical ETFMEDXDimensional - US Sustainability Core 1 ETFDFSUDimensional - US Core Equity 2 ETFDFACAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
